U.S. Department of Health & Human Services
HEAL Partnership Committee
About
The HEAL Partnership Committee (HPC) is a subgroup of the HEAL Multi-Disciplinary Working Group and provides assistance with defined tasks related to the development of new treatments for pain and addiction through Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, research. The HPC is responsible for making preliminary recommendations on the design of a template application and evaluation dossier for biopharmaceutical and device-based treatments to be tested through new clinical trials networks as part of the NIH HEAL Initiative. The working group incorporates input from the HPC into draft recommendations for NIH HEAL Initiative research, including on the process for the selection of assets for testing, the overall complement of assets to be tested at one time and the plan for expanding the portfolio to devices and biological treatments. Discussions of the HPC are made open to the public through videocasts and public meetings.
Meetings
Members
Christopher Austin, M.D.
Director, National Center for Advancing Translational Sciences, National Institutes of Health
Rebecca Baker, Ph.D.
Director, NIH HEAL Initiative, Office of the Director, National Institutes of Health
Patrizia Cavazzoni, M.D.
Deputy Director for Operations, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
John Dunlop, Ph.D.
Vice President, Neuroscience Research, Amgen
Christopher Flores, Ph.D.
Vice President and Glutamatergic Pathway Area Leader, Janssen Pharmaceutical Companies of Johnson & Johnson
Steven Joffe, M.D.
Founders Professor of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine
Walter Koroshetz, M.D.
Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health
John Marler, M.D.
Acting Clinical Deputy Director, Division of Neurological and Physical Medicine Devices, Center for Devices and Radiological Health, U.S. Food and Drug Administration
Mark Mintun, M.D.
Vice-President of Pain and Neurodegeneration Research and Clinical Development, Eli Lilly and Company; President, Avid Radiopharmaceuticals, Inc.
Richard Moscicki, M.D.
Executive Vice President and Science & Regulatory Advocacy Chief Medical Officer, Pharmaceutical Research and Manufacturers of America
Judith Paice, Ph.D., RN
Director, Cancer Pain Program, Division of Hematology-Oncology; Research Professor of Medicine, Northwestern University
Kurt Rasmussen, M.D.
Director, Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health
Cheryl Stucky, Ph.D.
Professor, Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin
Dave Thomas, M.S.
Vice President of Industry Research, Biotechnology Innovation Organization
Christin Veasley
Cofounder and Director, Chronic Pain Research Alliance
Kenneth Verburg, Ph.D.
Senior Vice President and Medicine Team Leader, Pfizer
Ashley Wittorf, M.S., M.B.A.
Executive Director, AdvaMed Accel
Clifford Woolf, M.D., Ph.D.
Professor of Neurology and Neurobiology, Harvard Medical School